Literature DB >> 12147205

The biological role of the Fas/FasL system during tumor formation and progression.

Ernst Reichmann1.   

Abstract

The cells of an organism are constantly exposed to conflicting environmental cues that signal cell survival or cell death. Survival signals are delivered by autocrine or paracrine factors that actively suppress a default death pathway. This default death pathway appears to be activated by dedicated death receptors such as Fas, the TRAIL-receptors and other tumor necrosis factor receptor superfamily proteins (TNFR SFPs). Our understanding of how these counteracting receptor systems are modulated during tumorigenesis is only moderate. Nevertheless, there is now broad evidence that susceptibility of tumor cells towards Fas-mediated apoptosis is largely reduced. In addition, tumor cells frequently exhibit de novo expression of Fas-ligand (FasL) which plays a significant role in local tissue destruction, metastatic spread and immune escape of the tumor cells. Restoring the apoptotic potential of cancer cells upon modulating the expression and activity of certain key components of the cell death machinery is an attractive and obvious therapeutic anti-cancer strategy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12147205     DOI: 10.1016/s1044-579x(02)00017-2

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  38 in total

1.  Glycyrrhetinic Acid inhibits cell growth and induces apoptosis in ovarian cancer a2780 cells.

Authors:  Venus Haghshenas; Shohreh Fakhari; Sako Mirzaie; Mohammadreza Rahmani; Fariba Farhadifar; Sara Pirzadeh; Ali Jalili
Journal:  Adv Pharm Bull       Date:  2014-08-25

2.  Polymorphisms of the FAS and FASL genes and risk of breast cancer.

Authors:  Wenmin Wang; Zhongqiu Zheng; Wenjie Yu; Hui Lin; Binbin Cui; Feilin Cao
Journal:  Oncol Lett       Date:  2011-12-28       Impact factor: 2.967

3.  FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck.

Authors:  Dapeng Lei; Erich M Sturgis; Li-E Wang; Zhensheng Liu; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

4.  Estrogens up-regulate the Fas/FasL apoptotic pathway in lactotropes.

Authors:  G Jaita; M Candolfi; V Zaldivar; S Zárate; L Ferrari; D Pisera; M G Castro; A Seilicovich
Journal:  Endocrinology       Date:  2005-08-11       Impact factor: 4.736

5.  Requirement of inositol 1,4,5-trisphosphate receptors for tumor-mediated lymphocyte apoptosis.

Authors:  Camia Steinmann; Megan L Landsverk; José M Barral; Darren Boehning
Journal:  J Biol Chem       Date:  2008-03-25       Impact factor: 5.157

6.  Apoptotic variants as predictors of risk of oropharyngeal cancer recurrence after definitive radiotherapy.

Authors:  Fenghua Zhang; Erich M Sturgis; Yan Sun; Yang Zhang; Qingyi Wei; Caiyun Zhang; Hongliang Zheng; Guojun Li
Journal:  Int J Cancer       Date:  2015-07-27       Impact factor: 7.396

7.  Fas palmitoylation by the palmitoyl acyltransferase DHHC7 regulates Fas stability.

Authors:  A Rossin; J Durivault; T Chakhtoura-Feghali; N Lounnas; L Gagnoux-Palacios; A-O Hueber
Journal:  Cell Death Differ       Date:  2014-10-10       Impact factor: 15.828

8.  Anti-gastric cancer active immunity induced by FasL/B7-1 gene-modified tumor cells.

Authors:  Shi-Ying Zheng; De-Chun Li; Zhi-De Zhang; Jun Zhao; Jin-Feng Ge
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

9.  Piwil2 inhibits keratin 8 degradation through promoting p38-induced phosphorylation to resist Fas-mediated apoptosis.

Authors:  Siyuan Jiang; Lianfang Zhao; Yilu Lu; Meiling Wang; Yuan Chen; Dachang Tao; Yunqiang Liu; Huaqin Sun; Sizhong Zhang; Yongxin Ma
Journal:  Mol Cell Biol       Date:  2014-08-11       Impact factor: 4.272

10.  CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells.

Authors:  Bryan C Barnhart; Patrick Legembre; Eric Pietras; Concetta Bubici; Guido Franzoso; Marcus E Peter
Journal:  EMBO J       Date:  2004-07-22       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.